2648257-56-9

Chemical Structure

STC-15
CAS No: 2648257-56-9

Formula: C₂₄H₂₅N₅O₂

Molecular Weight: 415.49
InChIKey: MFQFZLWCFZZHAI-UHFFFAOYSA-N
SMILES: O=C1C=C(C(NCC2=CC3=C(C=C(CNCC4CCC4)N3)C=C2)=O)N=C5C=CC=CN15

Biological Activity: STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases^[1]^[2]^[3].

Cat. No.	Product Name	Purity	Description
HY-156677	STC-15	99.90%	STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases.

References

[1]. Wesley Peter Blackaby, et al. Polyheterocyclic compounds as mettl3 inhibitors. Patent WO2021111124A1.
[2]. Ofir-Rosenfeld Y, et al. STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade[J]. European Journal of Cancer, 2022, 174: S123.
[3]. Ofir-Rosenfeld Y, et al. STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[C]//MOLECULAR CANCER THERAPEUTICS. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2023, 22(12).

Keywords:

STC-15

Name
Email *

	Sorry, but the email address you supplied was invalid.